-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

The Argument for Using Imatinib in CML

Program: Education Program
Session: Chronic Myeloid Leukemia: With Great Success Comes Great Responsibility
Sunday, December 2, 2018, 9:30 AM-11:00 AM
Seaport Ballroom A (Manchester Grand Hyatt San Diego)
Monday, December 3, 2018, 7:00 AM-8:30 AM
Room 6B (San Diego Convention Center)

Jane Apperley, MB ChB MD

Imperial College London, London, United Kingdom

Disclosures: Apperley: Novartis: Honoraria, Research Funding, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau; BMS: Honoraria, Speakers Bureau; Incyte: Honoraria, Speakers Bureau.

Previous Presentation | Next Presentation >>